StockDuty ← Dashboard Oct 08, 2026 03:03 PM ET
CatalystEU/UK

Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology

AstraZeneca partnership validates Myriad and SOPHiA prostate cancer technology.

What changed
AstraZeneca partnership validates Myriad and SOPHiA prostate cancer technology.
Why it matters
AstraZeneca partnership validates Myriad and SOPHiA prostate cancer technology. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
$RGA -0.6% — REINSURANCE GROUP OF AMERICA PRESENTS AT BARCLAYS 24TH ANNUAL GLOBAL FINANCIAL SERVICES CONFERENCE TRANSCRI →$GLEN →VOLKSWAGEN'S SURPRISE TURNAROUND DEAL AVERTS SHOWDOWN AS JOB CUTS LOOM - REUTERS - GNEWS →